We are live on ! Find out more
SION

Sionna Therapeutics

78 hedge funds and large institutions have $1.26B invested in Sionna Therapeutics in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 19 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

67% more capital invested

Capital invested by funds: $754M → $1.26B (+$506M)

20% more funds holding

Funds holding: 6578 (+13)

5% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

1.41% less ownership

Funds ownership: 98.47%97.06% (-1.4%)

Holders
78
Holders Change
+13
Holders Change %
+20%
% of All Funds
1.02%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
19
Increased
20
Reduced
19
Closed
6
Calls
Puts
Net Calls
Net Calls Change

SION Hedge Fund Activity: Q3 2025 in Review

78 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Sionna Therapeutics (SION) for Q3 2025, worth a combined $1.26B — up 67% from $754M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new SION positions and 6 closed out — a net gain of 13 holders — while 20 added to existing stakes and 19 trimmed.

The largest buyer was Vanguard Group, adding an estimated $11.2M. The largest seller was Braidwell, cutting an estimated $16.7M.

  • 78 institutional investors held Sionna Therapeutics (SION) as of Q3 2025, up from 65 in Q2 2025.
  • Funds reported $1.26B of Sionna Therapeutics stock for Q3 2025, up 67% quarter-over-quarter.
  • 19 funds opened new Sionna Therapeutics positions in Q3 2025 and 6 closed out, a net change of +13 holders.
  • The largest Sionna Therapeutics buyer in Q3 2025 was Vanguard Group, an estimated $11.2M added.
  • The largest Sionna Therapeutics seller in Q3 2025 was Braidwell, an estimated $16.7M sold.

Based on aggregated 13F filings for Q3 2025.